<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The most effective and safest option for the prevention of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and its sequelae--<z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality, <z:hpo ids='HP_0001297'>stroke</z:hpo>)--is primary prophylaxis </plain></SENT>
<SENT sid="1" pm="."><plain>Here, the management of arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo>--the most common cause underlying <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>--is of considerable importance </plain></SENT>
<SENT sid="2" pm="."><plain>In addition to blood pressure reduction, substances with an action of the autonomic <z:mp ids='MP_0008912'>nervous</z:mp> system and the renin-angiotensin-<z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> system (<z:chebi fb="2" ids="35457">ACE-inhibitors</z:chebi>, AT1 <z:chebi fb="68" ids="48706">antagonists</z:chebi>, beta blockers) have a positive effect on the remodeling, so-called, of the atrial myocytes, and thus on the occurrence of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> with its associated <z:hpo ids='HP_0001297'>stroke</z:hpo> risk </plain></SENT>
<SENT sid="3" pm="."><plain>For patients with elevated blood pressure, therefore, the therapeutic strategy should, in the individual case, give consideration to the possibility of exerting a positive effect on <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
</text></document>